Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 1/20 | 0.47 |
| ▸ | CA1 | P00915 | 1/20 | 0.47 |
| ▸ | CA2 | P00918 | 1/20 | 0.47 |
| ▸ | CA7 | P43166 | 1/20 | 0.47 |
| ▸ | CA9 | Q16790 | 1/20 | 0.47 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.47 |
| ▸ | ELANE | P08246 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 3/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.38 |
| ▸ | MEN1 | O00255 | 3/20 | 0.38 |
| ▸ | RAB9A | P51151 | 2/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | GPR52 | Q9Y2T5 | 1/20 | 0.37 |
| ▸ | USP2 | O75604 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | MMP1 | P03956 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Aspartic Acid SCHEMBL5445293 | 0.83 | SLC1A3 (0.38) | CA12CA1CA2CA7CA9 | |
| SCHEMBL6423366 | 0.81 | KMT2A (0.52) | MAPTGAACYP3A4KMT2AMEN1 | |
| SCHEMBL18127944 | 0.80 | CA12 (0.53) | CA12CA1CA2CA7CA9 | |
| SCHEMBL570471 | 0.80 | CA12 (0.70) | CA12CA1CA2CA7CA9 | |
| SCHEMBL5664136 | 0.80 | TSHR (0.53) | GAACYP3A4KMT2AMEN1RAB9A | |
| SCHEMBL3316733 | 0.78 | L3MBTL1 (0.46) | CA12CA1CA2CA7CA9 | |
| SCHEMBL3487721 | 0.77 | CA12 (0.50) | CA12CA1CA2CA7CA9 | |
| SCHEMBL5835110 | 0.77 | CA12 (0.50) | CA12CA1CA2CA7CA9 | |
| SCHEMBL22423696 | 0.76 | ALDH1A1 (0.58) | CA12CA1CA2CA7CA9 | |
| SCHEMBL12831173 | 0.76 | CA12 (0.48) | CA12CA1CA2CA7CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4397770-A1 | STABILISATION AND ISOLATION OF EXTRACELLULAR NUCLEIC ACIDS | PreAnalytiX GmbH (CH) | 2024-07-10 | — | — | EP | disclosed |
| EP-3401406-B1 | STABILISATION AND ISOLATION OF EXTRACELLULAR NUCLEIC ACIDS | PREANALYTIX GMBH (CH) | 2023-11-29 | — | — | EP | disclosed |
| US-20230285598-A1 | SULFOXONIUM YLIDE DERIVATIVES AS PROBES FOR CYSTEINE PROTEASE | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-09-14 | — | — | US | disclosed |
| EP-3447141-B1 | STABILISATION OF BIOLOGICAL SAMPLES | PREANALYTIX GMBH (CH) | 2020-08-05 | — | — | EP | disclosed |
| EP-2976425-B1 | STABILIZATION AND ISOLATION OF EXTRACELLULAR NUCLEIC ACIDS | QIAGEN GMBH (DE) | 2019-11-06 | — | — | EP | disclosed |
| EP-3401406-A1 | STABILISATION AND ISOLATION OF EXTRACELLULAR NUCLEIC ACIDS | QIAGEN GmbH (DE) | 2018-11-14 | — | — | EP | disclosed |
| EP-2976424-B1 | STABILISATION OF BIOLOGICAL SAMPLES | QIAGEN GMBH (DE) | 2018-10-03 | — | — | EP | disclosed |
| EP-2761020-B1 | STABILISATION AND ISOLATION OF EXTRACELLULAR NUCLEIC ACIDS | QIAGEN GMBH (DE) | 2018-06-13 | — | — | EP | disclosed |
| EP-2900834-B1 | STABILISATION OF BIOLOGICAL SAMPLES | QIAGEN GMBH (DE) | 2016-11-09 | — | — | EP | disclosed |
| EP-2761000-B1 | STABILISATION AND ISOLATION OF EXTRACELLULAR NUCLEIC ACIDS | PREANALYTIX GMBH (CH) | 2016-03-16 | — | — | EP | disclosed |
| US-20100068150-A1 | Selective Caspase Inhibitors | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2010-03-18 | — | — | US | disclosed |
| EP-2043672-A2 | SELECTIVE CASPASE INHIBITORS | The Board of Trustees of The Leland Stanford Junior University (US) | 2009-04-08 | — | — | EP | disclosed |
| WO-2008008264-A2 | SELECTIVE CASPASE INHIBITORS | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2008-01-17 | — | — | WO | disclosed |
| US-7247438-B1 | Methods of identifying agents which enhance caspase activity | DANA-FARBER CANCER INSTITUTE (US) | 2007-07-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100068150-A1 | Selective Caspase Inhibitors | CASP14, MLKL, CASP7 | CA12 2138/4885CA1 457/4885CA2 1944/4885 |
| US-20230285598-A1 | SULFOXONIUM YLIDE DERIVATIVES AS PROBES FOR CYSTEINE PROTEASE | CTSZ, CTSF, CTSL | CA12 294/4885CA1 278/4885CA2 446/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.